Sante Capital Fund’s Novavax NVAX Stock Holding History

Sante Capital Fund’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-3,523	Closed	-$748K	–	81
2021 Q2	$748K	Buy	+3,523	New	+$645K	0.31%	87

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sante Capital Fund's NVAX Position: Q3 2021 in Review

Sante Capital Fund sold out of Novavax (NVAX) in Q3 2021, closing a stake of 3,523 shares — an estimated $748K sold.

Sante Capital Fund first reported a position in NVAX in Q2 2021 and held it in 1 quarter. The position peaked at $748K in Q2 2021. 442 funds tracked by Wall St. Rank hold NVAX as of Q3 2021.

Sante Capital Fund reported no remaining Novavax position as of Q3 2021 after selling out during the quarter.
Sante Capital Fund sold 3,523 Novavax shares in Q3 2021, an estimated $748K.
Sante Capital Fund first reported a position in Novavax in Q2 2021 and held it in 1 quarter.
Sante Capital Fund's Novavax position peaked at $748K in Q2 2021.
442 funds tracked by Wall St. Rank held Novavax as of Q3 2021.

Based on Sante Capital Fund's 13F filing for Q3 2021, filed 15 Nov 2021.